Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are expected to live for at least 12 weeks.
• People who have a type of lung cancer called non-small cell lung cancer (NSCLC) that shows high levels of a protein called c-Met, as confirmed by a specific laboratory test approved for this trial.
• People who are able to provide a stored or fresh tumour tissue sample so that c-Met protein levels can be measured before the trial begins.
• People whose lung cancer has been confirmed through a tissue or cell sample and is of a specific type (non-squamous cell NSCLC) that has spread locally or to other parts of the body.
• People whose tumour has been tested and the result for a gene change called EGFR is known — but people whose cancer is driven by an EGFR gene change are not eligible.
• People whose cancer has gene changes in genes other than EGFR that are considered "actionable" (meaning a targeted treatment exists for them) may still be eligible.
• People whose cancer can be measured on scans using a standard set of medical guidelines.
• People who are fairly well and able to carry out daily activities with little or no limitation, as rated on a standard health scale (a score of 0 or 1 out of 5).
• People who have received no more than one prior course of chemotherapy for advanced or spread lung cancer (earlier chemotherapy given before or after surgery may also count if the cancer came back within 6 months of finishing it).
• People whose cancer has gotten worse after at least one prior treatment, with specific prior treatment requirements depending on whether the cancer has a known targetable gene change (confirm with trial site for details).
• People whom their treating doctor considers suitable to receive a chemotherapy drug called docetaxel.
• People who have cancer that has spread to the brain may still be eligible, provided the brain metastases have already been treated, there are no symptoms, and they are on a low or stable dose of steroids (no more than 10 mg per day of prednisone or equivalent) and/or anti-seizure medication for at least 2 weeks before joining the trial.

Who may not be able to join:

• People with new or untreated cancer spread to the brain, or brain metastases that are getting worse after treatment.
• People with cancer that has spread to the lining around the brain and spinal cord (leptomeningeal disease).
• People whose lung cancer is of certain specific types, including adenosquamous, neuroendocrine, or tumours with sarcomatoid features.
• People whose cancer is driven by an EGFR gene change.
• People who have previously been treated with antibodies that target c-Met, the specific drug telisotuzumab vedotin, or certain other antibody-based drug combinations targeting c-Met or containing a substance called monomethylauristatin E.
• People who have previously received the chemotherapy drug docetaxel.
• People with a history of another cancer, unless it was treated with the intention of cure, has shown no signs of return for at least 2 years, is considered low risk for coming back, and the person is not receiving any ongoing cancer treatment — or unless it was a type of non-melanoma skin cancer or pre-cancerous condition that was fully treated with no current signs of disease.
• People with a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-related lung inflammation, or unexplained lung inflammation — or people who show signs of active lung inflammation on a recent chest scan. A history of scarring in the lungs from prior radiation is also not permitted.
• People who still have unresolved side effects rated moderate or worse (Grade 2 or higher) from previous cancer treatment, except for hair loss or anaemia. (People with hormone problems caused by prior treatment who have no symptoms and are on a stable hormone replacement dose may still be eligible — confirm with trial site.)
• People who have had major surgery within 21 days before joining the trial.
• People with certain other significant medical conditions as outlined in the full trial protocol (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.